Research Papers:

A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma

Wen Wang, Lu Zhang, Zheng Wang, Fan Yang, Haoyuan Wang, Tingyu Liang, Fan Wu, Qing Lan, Jiangfei Wang and Jizong Zhao _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:69991-69999. https://doi.org/10.18632/oncotarget.11726

Metrics: PDF 2987 views  |   HTML 3490 views  |   ?  


Wen Wang1,2,3,7, Lu Zhang5, Zheng Wang2,3,7, Fan Yang2,3,7, Haoyuan Wang6,7, Tingyu Liang2,3,7, Fan Wu3,4,7, Qing Lan1, Jiangfei Wang2,4,7, Jizong Zhao2,1,8

1Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China

2Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

3Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China

4Brain Tumor Center, Beijing Institute for Brain Disorders, Beijing, China

5Department of Ophthalmology, School of Medicine, Shandong University, Jinan, China

6Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China

7Chinese Glioma Cooperative Group (CGCG), Beijing, China

8China National Clinical Research Center for Neurological Diseases, Beijing, China

Correspondence to:

Jizong Zhao, email: [email protected]

Keywords: signature, MGMT, prognosis, glioblastoma, RNA-Seq

Received: February 27, 2016     Accepted: August 09, 2016     Published: August 31, 2016


Glioblastoma is the most malignant tumor and has high mortality rate. The methylated prompter of MGMT results in chemotherapy sensitivity for these patients. However, there are still other factors that affected the prognosis for the glioblastoma patients with similar MGMT methylation status. We developed a signature with three genes screened from the whole genome mRNA expression profile from Chinese Glioma Genome Atlas (CGGA) and RNAseq data from The Cancer Genome Atlas (TCGA). Patients with MGMT methylation in low risk group had longer survival than those in high risk group (median overall survival 1074 vs. 372 days; P = 0.0033). Moreover, the prognostic value of the signature was significant difference in cohorts stratified by MGMT methylation and chemotherapy (P=0.0473), while there is no significant difference between low and high risk group or unmethylated MGMT patients without chemotherapy. Multivariate analysis indicated that the risk score was an independent prognosis factor (P = 0.004). In conclusion, our results showed that the signature has prognostic value for patients with MGMT promoter-methylated glioblastomas based on bioinformatics analysis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11726